Table 2 Medians of inflammatory and cardiometabolic biomarkers over time by assigned treatment
Treatment group | ||||||
|---|---|---|---|---|---|---|
Aspirin only | Pravastatin only | Aspirin and pravastatin | ||||
Biomarker | N | Median (range) | N | Median (range) | N | Median (range) |
hsCRP (mg/L) | ||||||
Baseline | 8 | 2.1 (0.2, 4.9) | 7 | 3.3 (0.4, 8.8) | 6 | 3.6 (0.3, 12.0) |
Week 2 | 7 | 1.0 (0.2, 4.2) | 7 | 2.9 (0.3, 5.1) | 5 | 1.4 (0.3, 16.2) |
Week 4 | 3 | 2.3 (0.8, 4.0) | 4 | 1.1 (0.6, 4.5) | 4 | 0.9 (0.3, 11.1) |
IL-1 (pg/mL) | ||||||
Baseline | 8 | 3.9 (3.9, 3.9) | 7 | 3.9 (3.9, 4.0) | 7 | 3.9 (3.9, 4.0) |
Week 2 | 7 | 3.9 (3.9, 3.9) | 7 | 3.9 (3.9, 4.0) | 5 | 3.9 (3.9, 4.0) |
Week 4 | 3 | 3.9 (3.9, 4.0) | 4 | 4.0 (3.9, 4.0) | 4 | 3.9 (3.9, 4.0) |
IL-6 (pg/mL) | ||||||
Baseline | 8 | 1.9 (0.7, 3.0) | 7 | 3.4 (0.7, 41.1) | 6 | 3.2 (0.7, 15.4) |
Week 2 | 7 | 2.0 (0.7, 3.1) | 7 | 3.4 (0.7, 8.7) | 5 | 2.4 (0.7, 7.6) |
Week 4 | 3 | 2.8 (0.7, 3.1) | 4 | 2.1 (0.7, 5.5) | 4 | 2.4 (0.7, 10.2) |
Total cholesterol (mg/dL) | ||||||
Baseline | 8 | 192 (120, 238) | 6 | 180 (159, 256) | 7 | 166 (145, 188) |
Week 2 | 6 | 183 (153, 209) | 5 | 173 (124, 224) | 5 | 148 (137, 191) |
Week 4 | 3 | 186 (157, 232) | 4 | 179 (140, 190) | 3 | 147 (116, 154) |
LDL cholesterol (mg/dL) | ||||||
Baseline | 8 | 125 (79, 189) | 6 | 115 (92, 145) | 7 | 102 (7, 122) |
Week 2 | 6 | 114 (83, 143) | 5 | 87 (58, 130) | 5 | 78 (60, 101) |
Week 4 | 3 | 113 (104, 189) | 4 | 104 (73, 130) | 3 | 90 (52, 101) |
HDL cholesterol (mg/dL) | ||||||
Baseline | 8 | 54 (30, 83) | 6 | 61 (46, 87) | 7 | 61 (33, 82) |
Week 2 | 6 | 64 (34, 79) | 5 | 64 (51, 82) | 5 | 60 (36, 75) |
Week 4 | 3 | 40 (38, 62) | 4 | 60 (47, 72) | 3 | 59 (32, 60) |
Triglycerides (mg/dL) | ||||||
Baseline | 8 | 111 (33, 311) | 6 | 87 (31, 146) | 7 | 75 (73, 121) |
Week 2 | 6 | 71 (37, 229) | 5 | 105 (48, 138) | 5 | 98 (54, 166) |
Week 4 | 3 | 92 (31, 97) | 4 | 73 (35, 142) | 3 | 113 (73, 206) |